Jpmorgan Chase & CO Logic Bio Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.29 - $0.67 $6 - $16
24 New
24 $0
Q1 2022

May 11, 2022
SELL
$0.61 - $2.49 $209 - $856
-344 Closed
0 $0
Q4 2021

Feb 10, 2022
BUY
$2.2 - $4.53 $756 - $1,558
344 New
344 $1,000

About LogicBio Therapeutics, Inc.

LOGC Quotes by TradingView
  • Ticker LOGC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,962,700
  • Description
  • LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...
More about LOGC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email